Seres Therapeutics (MCRB) officer Brady Kelly reports stock holdings
Rhea-AI Filing Summary
Seres Therapeutics insider Brady Kelly has filed an initial ownership report showing existing equity holdings in the company. The filing lists several stock options to purchase Common Stock, including one covering 11,700 shares at an exercise price of 15.6400 per share expiring on February 6, 2035, plus additional options with exercise prices around 22.0000 to 23.0000 per share expiring in 2034. Kelly also holds Restricted Stock Units tied to 358 and 730 shares of Common Stock and directly owns 8,441 shares of Common Stock following the reported positions. The footnotes explain that these options and RSUs vest over time, with 25% already vested and the remainder scheduled to vest in 12 equal quarterly installments after the initial vesting dates.
Positive
- None.
Negative
- None.
Insider Trade Summary
10 transactions reported
Mixed
10 txns
Insider
Brady Kelly
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 22,079 shares (Direct);
Restricted Stock Units — 1,088 shares (Direct);
Common Stock — 8,441 shares (Direct)
Footnotes (6)
- F1. The options were granted on February 14, 2024. The option vested as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
- F2. The options were granted on February 7, 2025. The option vested as to 25% of the shares on February 7, 2026. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
- F3. The stock options are fully vested.
- F4. The options were granted on February 12, 2024. The option vested as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
- F5. The restricted stock units were granted on February 3, 2023. The restricted stock units vested as to 25% of the shares on February 15, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
- F6. The restricted stock units were granted on February 14, 2024. The restricted stock units vested as to 25% of the shares on February 15, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Seres Therapeutics (MCRB) Form 3 filing show for Brady Kelly?
The Form 3 shows Brady Kelly’s existing equity holdings in Seres Therapeutics, including several stock option grants, Restricted Stock Units, and 8,441 shares of Common Stock held directly after the reported positions, establishing a baseline for future insider transaction reporting.
What stock options for Seres Therapeutics (MCRB) does Brady Kelly currently report?
Brady Kelly reports multiple stock options to buy Seres Therapeutics Common Stock, including an option over 11,700 underlying shares at an exercise price of $15.6400 per share expiring February 6, 2035, along with several additional options with exercise prices around $22–$23 expiring in 2034.
How do Brady Kelly’s Seres Therapeutics (MCRB) stock options vest over time?
The footnotes state that each option vested 25% on its first vesting date, with the remaining 75% scheduled to vest in 12 equal quarterly installments thereafter, creating a multi‑year vesting schedule that gradually delivers full vesting if Kelly remains with Seres Therapeutics.
What Restricted Stock Units in Seres Therapeutics (MCRB) does Brady Kelly hold?
Brady Kelly holds Restricted Stock Units tied to 358 and 730 shares of Seres Therapeutics Common Stock. These RSUs vested 25% on their initial vesting dates, with the remainder vesting in 12 equal quarterly installments, and they have no expiration date according to the footnotes.